WEBULL
WebtradeDownload

Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?

Simply Wall St · 3d ago

HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors.

See our latest analysis for HBM Holdings.

The HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is about 9x. This combination of recent share price momentum and long-term total shareholder return suggests investors are responding to pipeline progress and reassessing the company’s risk and growth profile.

If you are looking for other potential biotech opportunities around cancer and immunology, it could be a good moment to see what is moving in 130 healthcare AI stocks

The recent surge in HBM Holdings could reflect investors giving more credit to the antibody platform and pipeline rather than a simple mood swing in the market. How far does that sentiment shift stretch the current valuation?

Price to Earnings of 20x for HBM Holdings: Is it justified?

HBM Holdings is trading on a P/E of 20x at a last close of HK$16.54, which screens as more expensive than both its fair-value P/E and its immediate peer group.

The P/E ratio compares the company’s share price to its earnings per share. For a biopharmaceutical business like HBM Holdings, this multiple is often used as a quick check on how the market is valuing today's earnings against expectations for future profitability and commercialisation of the pipeline.

Here, the picture is mixed. On one hand, the stock is described as good value relative to the Hong Kong Biotechs industry average P/E of 26.2x, which suggests the broader sector trades on an even higher earnings multiple. On the other hand, the same 20x P/E is flagged as expensive versus a peer average of 19.7x, and also versus an estimated fair P/E of 12x that the market could move towards if sentiment cools or earnings forecasts adjust.

Relative to the industry, the current 20x P/E looks cheaper than the wider Biotechs group but richer than both similar peers and that 12x fair ratio benchmark, which together point to a market that is already assigning a premium to HBM Holdings' earnings compared with what the regression based fair ratio suggests.

Explore the SWS fair ratio for HBM Holdings

Result: Price-to-Earnings of 20x (OVERVALUED)

However, that optimism around HBM Holdings could be challenged if revenue growth slows further, or if key antibody programs encounter clinical or regulatory setbacks.

Find out about the key risks to this HBM Holdings narrative.

Another View on HBM Holdings Using Our DCF Model

While the 20x P/E suggests HBM Holdings carries a premium to its fair ratio of 12x, the SWS DCF model presents a different perspective. At HK$16.54, the stock trades above an estimated future cash flow value of HK$8.98, which implies limited margin for error if expectations change.

For investors weighing earnings multiples against cash flow based fair value, it can be useful to understand how this gap is built up before making any move. Look into how the SWS DCF model arrives at its fair value.

2142 Discounted Cash Flow as at Aug 2026
2142 Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 270 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around HBM Holdings, it makes sense to review the numbers yourself and consider how comfortable you are with both the pipeline progress and the valuation. To evaluate the potential upside alongside the factors that could limit the stock, review the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond HBM Holdings?

If HBM Holdings has your attention, do not stop here. Broaden your watchlist with other opportunities that fit clear, well defined criteria using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.